## **QIBA PET Amyloid Biomarker Committee**

08 April 2016 at 9:00 AM CT (GMT-6)
Call Summary

In attendance:

Eric Perlman, MD (Co-Chair) Anne Smith, PhD (Co-Chair) William Bridge, MS Susan De Santi, PhD Paul Kinahan, PhD Martin Lodge, PhD Dawn Matthews, MS, MBA Nancy Obuchowski, PhD Sara Sheikbahaei, PhD Charles Smith, MSCS John Sunderland, PhD Jean-Luc Vanderheyden, PhD Richard Wahl, MD, FACR **RSNA** Joe Koudelik Julie Lisiecki

## **QIBA Round-6 Project Proposals**

- Proposals are being drafted by project champions
  - Phantom and DRO (Drs. Sunderland and Kinahan)
  - o Tracer uptake time differential effect (Drs. Boellaard and Vanderheyden)
- Feasibility test collaboration with ADNI (may be considered for future funding)
  - o Modeled after FDG Tumor Profile work
- Software/Reader variability project modeled after Dr. Wahl's project for the FDG Tumor Profile
  - o Compare different analysis packages and readers (unless software is fully automated)
  - o Dr. Obuchowski is willing to offer statistical support for this project
  - ADNI may be a good partner or provide a good dataset to use
  - Advantageous to incorporate different tracers: PET amyloid radiopharmaceutical vendors may contribute data
- Scanner reconstruction/image analysis impact on SUVR project
  - o Ms. Matthews and Dr. Smith may review major points with the Round-5 project
  - o Group guidance would be helpful topics under investigation include:
    - Difference between recon algorithms (FBP, OSEM, PSF and their TOF versions)
    - Number of iterations (OSEM: 2, 3, 4, 5, 6)
    - Gaussian filter size (OSEM: 2,5,7 mm)
  - Ms. Matthews plans to submit a project proposal on this topic and is open to suggestions
  - Dr. Smith to contact Dr. DeSanti about obtaining Siemens mCT scanner data from Piramal (done)
- Project proposals (including budget detail) are due to QIBA by April 15<sup>th</sup>: <a href="mailto:qiba@rsna.org">qiba@rsna.org</a>

## **Profile**

- The Profile was last updated on April 7, 2016.
- As there are over 100 different comments, Dr. Perlman has enlisted the aid of a colleague to act as interim Profile editor to help the group and clean up this latest version for readability.
- Some open issues remain that will require with the input of physics experts
- Dr. Obuchowski will also need to re-review the statistics sections to check for accuracy
- No additional confounders were found
- SUVr will be used instead of absolute SUV
- Some additional details are needed for the Patient Prep section 3.1.2

Action item: RSNA staff to re-distribute NIBIB application forms / details to all NM BC leaders

**April Nuclear Medicine WebEx Calls:** 

**Biomarker Committees:** 

Apr 15: No call after QIBA Mtg

Apr 22: SPECT BC Apr 29: TBD

SPECT Task Forces: (Tuesdays, 2 pm CT)

Apr 19: Phantoms / DRO – Drs. Dickson & Zimmerman

Apr 26: Clinical / Literature Review – Dr. Seibyl